In addition, patients are included from 1990 onwards, providing more actual survival rates, since patients with MEN1 are a biochemically screened population and gastric acid hypersecretion‐related deaths have been rarely reported over the last two decades.9, 10 In the present study, OS was used as outcome, because OS is more informative and establishing gastrinoma‐related deaths (disease‐specific survival) is challenging in the presence of multiple MEN1 manifestations. The gene discussed is MEN1; the disease is gastrin-producing neuroendocrine tumor.